U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
ACADThe U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome.
The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023.
Acadia Pharmaceuticals Announces Trofinetide New Drug Application For Treatment Of Rett Syndrome Has Been Accepted For Filing And Review By U.S. FDA
ACADACADIA Pharmaceuticals: Q1 Earnings Insights
ACADACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Acadia Pharmaceuticals Reaffirms FY22 NUPLAZID Net Sales Guidance $510M-$560M
ACADACADIA Pharmaceuticals Q1 EPS $(0.70) Misses $(0.60) Estimate, Sales $115.50M Miss $121.92M Estimate
ACADACADIA Pharmaceuticals's Earnings Outlook
ACADACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that ACADIA Pharmaceuticals will report an earnings per share (EPS) of $-0.60.
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
ACADHere's a roundup of top developments in the biotech space over the last 24 hours.
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting To Review Resubmission Of Supplemental New Drug Application For NUPLAZID (pimavanserin) For Treatment Of Alzheimer's Disease Psychosis Scheduled For Jun. 17, 2022
ACAD